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Abstract
Circadian timing largely modifies efficacy and toxicity of many anticancer drugs. Recent findings suggest that optimal
circadian delivery patterns depend on the patient genetic background. We present here a combined experimental and
mathematical approach for the design of chronomodulated administration schedules tailored to the patient molecular
profile. As a proof of concept we optimized exposure of Caco-2 colon cancer cells to irinotecan (CPT11), a cytotoxic drug
approved for the treatment of colorectal cancer. CPT11 was bioactivated into SN38 and its efflux was mediated by ATP-
Binding-Cassette (ABC) transporters in Caco-2 cells. After cell synchronization with a serum shock defining Circadian Time
(CT) 0, circadian rhythms with a period of 26 h 50 (SD 63 min) were observed in the mRNA expression of clock genes REV-
ERBa, PER2, BMAL1, the drug target topoisomerase 1 (TOP1), the activation enzyme carboxylesterase 2 (CES2), the
deactivation enzyme UDP-glucuronosyltransferase 1, polypeptide A1 (UGT1A1), and efflux transporters ABCB1, ABCC1, ABCC2
and ABCG2. DNA-bound TOP1 protein amount in presence of CPT11, a marker of the drug PD, also displayed circadian
variations. A mathematical model of CPT11 molecular pharmacokinetics-pharmacodynamics (PK-PD) was designed and
fitted to experimental data. It predicted that CPT11 bioactivation was the main determinant of CPT11 PD circadian rhythm.
We then adopted the therapeutics strategy of maximizing efficacy in non-synchronized cells, considered as cancer cells,
under a constraint of maximum toxicity in synchronized cells, representing healthy ones. We considered exposure schemes
in the form of an initial concentration of CPT11 given at a particular CT, over a duration ranging from 1 to 27 h. For any dose
of CPT11, optimal exposure durations varied from 3h40 to 7h10. Optimal schemes started between CT2h10 and CT2h30, a
time interval corresponding to 1h30 to 1h50 before the nadir of CPT11 bioactivation rhythm in healthy cells.
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Introduction
Circadian timing largely modifies efficacy and toxicity of many
anticancer drugs. Chronomodulated administration schemes for
patients have been designed based on chronotoxicity results
obtained in mice and subsequently validated in clinical trials in
which all patients have received the same regimen. However
recent findings highlight the need of personalizing circadian
delivery according to the patient gender and genetic background
[1,2]. The systems biology approach presented here aims at
designing optimal chronotherapeutics schedules using mathemat-
ical models fitted to the patient molecular profile. We propose here
an in vitro proof of concept which focuses on irinotecan (CPT11), a
cytotoxic drug approved for the treatment of colorectal cancer [3].
CPT11 efficacy and toxicity display circadian rhythms in mice
[4,5] and in patients [6,7]. Its circadian administration is here
optimized in cell culture using a combined experimental and
mathematical approach.
Most biological functions in mammals such as rest-activity, body
temperature or hormonal secretions, display rhythms of period
between 20 and 28 h called circadian rhythms. Circadian changes
are coordinated by the suprachiasmatic nuclei (SCN), an
endogenous pacemaker located in the hypothalamus. SCN
functions display an intrinsic genetically-determined period which
is entrained and calibrated at precisely 24 h by environmental
synchronizers such as the alternation of days and nights, socio-
professional routines and meal timing [8]. This central pacemaker
controls through rhythmic physiological signals the molecular
circadian clock present in each nucleated cell. The cellular
molecular clock is constituted of interconnected regulatory loops
involving about 15 clock genes such as CLOCK, PER, BMAL,o r
REV-ERBa. Those genes display circadian rhythms in their
expression and generate in turn circadian oscillations of various
gene and protein amounts. [9]. In particular, many enzymes
involved in drug metabolism, cell cycle, DNA repair or apoptosis
display circadian variations and induce rhythms in the toxicity and
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often disrupted in tumor tissues. This temporal difference between
normal and cancer cells is exploited in cancer chronotherapeutics
by targeting the circadian time of minimum toxicity in healthy
cells [8].
In vitro chronotherapeutics studies derive their rationale from the
fact that each nucleated cell is endowed with a molecular circadian
clock. Nevertheless, in the absence of external synchronizer, the
millions of cells contained in a Petri dish oscillate neither with the
same phase nor with the same period [10,11]. Synchronization
with a serum shock (exposure to a large amount of nutrients [12]),
drugs [13] or temperature cycles [14] resets the cellular clocks
which then oscillate in synchrony with a circadian period. Of note,
the serum shock may activate transcription factors which induce a
transient overshoot in the expression of some genes during the first
periods.
As CPT11 is highly toxic for the colon mucosa and efficient
against colorectal adenocarcinomas, the human colon cancer cell
line Caco-2 was chosen for this in vitro study. Caco-2 cells
constitute a well-established cellular model for investigating both
colon physiology and colon cancer susceptibility to drugs.
Furthermore, they do express clock genes [15].
Concerning CPT11 PK, the drug is bioactivated by CESs into
SN38 which is 100 to 1000-fold more cytotoxic (Figure 1, [16,17]).
SN38 is deactivated into SN38G by glucuronidation through
mainly UGT1A1 [18] and other UGT1As [19]. CPT11 cellular
uptake is passive in intestinal cells whereas that of SN38 occurs
passively only at low pH when the carboxylate form is
predominant. The uptake of SN38 lactone form is possibly
mediated by active mechanisms [20,21]. CPT11 and its
metabolites are actively expelled outside of the cells by transporters
of the ABC super-family. CPT11 is preferentially transported by
ABCB1, ABCC1 and ABCC2; SN38 by ABCG2, ABCC1 and
ABCC2; and SN38G by ABCC2 and ABCG2 [22,23].
CPT11 is an inhibitor of TOP1, an enzyme present in all
nucleated cells (Figure 1, [24]). Its function is to relax DNA which
may be supercoiled by several processes including replication and
transcription. TOP1 binds to DNA and cuts one strand which is
thus able to rotate around the molecule. Then TOP1 dissociates
from DNA allowing the reconnection of the broken strand.
CPT11 and its active metabolite SN38 prevent TOP1 religation
by creating DNA/TOP1/drug complexes which can spontane-
ously dissociate but have a longer lifetime than DNA/TOP1
Author Summary
Treatment timing within the 24-h timescale, that is,
circadian (circa, about; dies, day) timing, can change by
several fold the tolerability and antitumor efficacy of
anticancer agents both in experimental models and in
cancer patients. Chronotherapeutics aims at improving the
tolerability and/or the efficacy of medications through the
administration of treatments according to biological
rhythms. Recent findings highlight the need of individu-
alizing circadian delivery schedules according to the
patient genetic background. In order to address this issue,
we propose a combined experimental and mathematical
approach in which molecular mathematical models are
fitted to experimental measurements of critical biological
variables in the studied experimental model or patient.
Optimization procedures are then applied to the calibrated
mathematical model for the design of theoretically optimal
circadian delivery patterns. As a first proof of concept we
focused on the anticancer drug irinotecan. A mathematical
model of the drug molecular PK-PD was built and fitted to
experimental data in Caco-2 colon cancer cells. Numerical
algorithms were then applied to theoretically optimize the
chronomodulated exposure of Caco-2 cells to irinotecan.
Figure 1. CPT11 PK-PD molecular pathways considered in Caco-2 cells. CPT11 in the extracellular medium (CPTout) diffuses passively
through the cell membrane and reaches the intracellular compartment (CPTin). It is then bioactivated into SN38 (SNin) through CESs. SNin is
deactivated into SN38G (SNGin)t h r o u g hU G T 1 A s .CPTin, SNin and SNGin a r ee x p e l l e do u t s i d eo ft h ec e l lb yA B Ct r a n s p o r t e r s
(CPTout,SNout,SNGout). TOP1 is an enzyme which relaxes supercoiled DNA by creating transient DNA/TOP1 complexes. SNin traps them into
SN38/DNA/TOP1 reversible complexes which becomes irreversible after collision with replication or transcription mechanisms, thus triggering DNA
repair and possibly apoptosis.
doi:10.1371/journal.pcbi.1002143.g001
Optimization of Irinotecan Circadian Delivery
PLoS Computational Biology | www.ploscompbiol.org 2 September 2011 | Volume 7 | Issue 9 | e1002143complexes. Collisions between those ternary reversible complexes
and replication or transcription mechanisms convert them into
irreversible covalent DNA damage which triggers DNA repair and
possibly leads to cell cycle arrest and apoptosis [24,25]. The
amount of TOP1 complexes on the DNA has been experimentally
correlated to CPT11 cytotoxicity both in vitro and in patients
[26,27].
Several genes and proteins involved in CPT11 PK-PD display
circadian rhythms in mice including the drug target top1, the
activation enzymes ces1 and ces2, the deactivation enzyme ugt1a1
and the efflux transporters abcb1a, abcb1b and abcc2 [2,28–30].
We implemented here a combined experimental and mathe-
matical approach for optimizing CPT11 circadian delivery
according to the critical molecular determinants of its chron-
otoxicity.
Results
CPT11 PK-PD in non-synchronized cells
CPT11 accumulated into non-synchronized Caco-2 cells
(Figure 2). Approximately 0.1% of its total amount was
bioactivated into SN38. Verapamil drastically increased the
intracellular accumulation of CPT11 and slightly decreased its
extracellular concentration. This confirmed the influence on
CPT11 efflux of ABCB1, ABCC1 and ABCC2, three transporters
inhibited by verapamil. The increase in CPT11 intracellular
concentration in presence of verapamil resulted in increased SN38
production. Nevertheless SN38 intracellular concentration re-
mained similar whereas SN38 extracellular concentration in-
creased in presence of the inhibitor which therefore did not alter
SN38 efflux.
Circadian control of CPT11 PK-PD in synchronized cells
Three clock genes (REV-ERBa, PER2, BMAL1) and seven
pharmacological genes (TOP1, UGT1A1, CES2, ABCB1, ABCC1,
ABCC2, ABCG2) displayed circadian rhythms in their mRNA
expression in synchronized Caco-2 cells (Figure 3). Experimental
time series were fitted to equation 12 (cf. Materials and Methods)
and a common period of 26 h 50 (SD 63 min) was found (Table 1).
Oscillations were damped for all genes except BMAL1 and CES2.
Some variability was encountered between the four experiments
which explained the weak amplitude of CES2 rhythm (Text S1).
Figure 2. Time evolution of CPT11, SN38 and SN38G extra- and intracellular concentrations during CPT11 exposure. Drug
concentrations in absence (p) or presence (&) of verapamil are averages of four data points obtained from two independent experiments (+SEM).
Solid and dashed curves are the best fits of the PK-PD mathematical model in absence or presence of verapamil respectively. A,B,C: extracellular
concentrations of CPT11, SN38 and SN38G; D, E, F: intracellular concentrations of CPT11, SN38 and SN38G (sum of free and DNA-bound molecules).
doi:10.1371/journal.pcbi.1002143.g002
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consistent rhythm was found in its nucleic protein level (data not
shown).
DNA-bound TOP1 protein amount was equal to 47% (SEM
5.2%) of TOP1 total protein quantity after exposure to CPT11 at
CT14 as compared to 35.5% (SEM 1.8%) after exposure at CT28
(p=0.05; Figure 4).
CPT11 molecular PK-PD mathematical model
The CPT11 PK-PD model describes the molecular pathways
occurring within a population of quiescent Caco-2 cells exposed to
the drug. The modeled biological system consists in one million of
Caco-2 cells attached to the bottom of a Petri dish and covered
with extracellular medium. Vout stands for the volume of
extracellular medium and is set to 2:5:10{3L. Vin represents the
total intracellular volume equal to the experimentally-determined
volume of a single cell multiplied by the number of cells. It is equal
to 8:106pL. Mathematical variables represent concentrations in
the extracellular compartment or intracellular concentrations
averaged on the cell population.
The mathematical model of CPT11 molecular PK-PD
computes the cytotoxicity induced in Caco-2 cells by any given
exposure schedule. CPT11 activity is assessed by the amount of
irreversible DNA/TOP1/SN38 complexes, chosen as the output
variable because of its experimentally-proven correlation with
CPT11 cytotoxicity [26,27].
Molecular pathways are modeled according to information
from literature and experimental results obtained in Caco-2 cells.
Briefly, CPT11, SN38 and SN38G cellular uptakes are assumed to
be passive as these molecules are mainly under their carboxylate
form at the pH of experiments (pH 7.8). Cellular uptake is
modeled as a diffusion across a membrane, the contact surface
between cells and extracellular medium being proportional to the
number of cells [31]. CPT11 and SN38 efflux are mediated
respectively by ABC CPT (mainly standing for the sum of
activities of ABCB1, ABCC1, ABCC2) and ABC SN (for
ABCC1, ABCC2, ABCG2). Efflux follows Michaelis-Menten
kinetics [32,33]. Diffusion from inside to outside of the cells is
neglected. CPT11 is bioactivated into SN38 through CES
representing the sum of all carboxylesterases activity. This
Figure 3. Gene expression circadian rhythm in synchronized Caco-2 cells. mRNA level of three clock genes (REV-ERBa, PER2, BMAL1) and
seven genes involved in CPT11 PK-PD (TOP1, UGT1A1, CES2, ABCB1, ABCC1, ABCC2, ABCG2) displayed circadian variations. Experimental results are
averages of four independent experiments for REV-ERBa, TOP1, UGT1A1, and CES2; and three independent experiments for PER2, BMAL1, ABCB1,
ABCC1, ABCC2, and ABCG2 (mean+SEM). The solid curve is the best fit of equation 12 (see Table 1 for parameter values).
doi:10.1371/journal.pcbi.1002143.g003
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d½CPTout 
dt
Vout
Vin
~{kupCPT½CPTout 
z
VeffCPT½ABC CPT ½CPTin 
KeffCPTz½CPTin 
ð1Þ
d½CPTin 
dt
~kupCPT½CPTout {
VeffCPT½ABC CPT ½CPTin 
KeffCPTz½CPTin 
{
Vces½CES ½CPT11in 
Kcesz½CPT11in 
ð2Þ
SN38 is expected to be deactivated into SN38G in Caco-2 cells
as UGT1A1 was expressed (Figure 3). This reaction is modeled by
Michaelis-Menten kinetics [19,34,37]. The mathematical variable
UGT stands for the sum of UGT1As enzymatic activities.
d½SNout 
dt
Vout
Vin
~{kupSN½SNout z
VeffSN½ABC SN ½SNin 
KeffSNz½SNin 
ð3Þ
d½SNin 
dt
~kupSN½SNout {
VeffSN½ABC SN ½SNin 
KeffSNz½SNin 
z
Vces½CES ½CPTin 
Kcesz½CPTin 
ð4Þ
Table 1. Parameter values of circadian mRNA expressions in synchronized Caco-2 cells.
l (h
”1) P (a.u.) S (a.u.) w (h, min) R (a.u.)
REV{ERBa 0:04+0:01 0:21+0:06 0:24+0:05 10h41+71min 0:14+0:03
PER20 :08+0:01 0:83+0:52 1:65+0:58 h 3 7 +74min 0:79+0:18
BMAL10 0 :83+0:07 0:41+0:09 17h04+75min 0
TOP10 :02+0:01 0:7+0:20 :59+0:15 14h30+96min 0:41+0:11
UGT1A10 :06+0:01 0:65+0:13 0:68+0:16 14h32+65min 0:27+0:06
CES20 0 :87+0:04 0:13+0:05 16h40+176min 0
ABCB10 :03+0:01 1:06+0:24 0:84+0:3 15h58+60min 0:09+0:08
ABCC10 :06+0:02 0:17+0:09 0:18+0:07 10h28+144min 0:25+0:05
ABCC20 :08+0:004 1:44+0:27 1:32+0:23 14h50+51min 0:36+0:05
ABCG20 :08+0:007 0:63+0:13 0:69+0:12 13h36+43min 0:09+0:02
Values correspond to means+SD. They were estimated by fitting equation 12 to experimental data of Figure 3 by a bootstrap approach (Text S1), a.u.= arbitrary units.
doi:10.1371/journal.pcbi.1002143.t001
Figure 4. Circadian rhythm of CPT11-induced TOP1 complexes on DNA in synchronized Caco-2 cells. Experimental results are averages
of four independent experiments (+SEM) after exposure to CPT11 at CT14 and CT28. The dotted line is the circadian variation of TOP1 complexes
(sum of variables DNATOP1, Compl and Icompl) computed using the PK-PD mathematical model fitted to all experimental data (see Results).
doi:10.1371/journal.pcbi.1002143.g004
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Vugt½UGT ½SNin 
Kugtz½SNin 
{kf2½DNATOP1 ½SN38in zkr2½Compl ð 5Þ
As SN38G is inactive, its extra- and intracellular concentrations do
not exert any influence on the output of the model which is the
drug activity. Nevertheless, those quantities can be computed
using the following equations in which transport parameters of
SN38G were assumed to be equal to the ones of SN38, for the sake
of simplicity:
d½SNGout 
dt
Vout
Vin
~{kupSN½SNGout z
VeffG½ABC SN ½SNGin 
KeffSNz½SNGin 
ð6Þ
d½SNGin 
dt
~kupSN½SNGout {
VeffSN½ABC SN ½SNGin 
KeffSNz½SNGin 
z
Vugt½UGT ½SNin 
Kugtz½SNin 
ð7Þ
CPT11 ability to bind to TOP1 is neglected so that SN38 is the
only molecule able to stabilize DNA/TOP1 complexes into DNA/
TOP1/SN38 ones (Compl). Those ternary complexes are able to
spontaneously dissociate or can be converted into irreversible
complexes (Icompl) after collision with transcription or replication
mechanisms. The DNAfree variable represents the number of
available binding sites for TOP1 on the DNA (Text S1). Those
entry sites are assumed to occur every kentry pairs of bases. DNA total
quantity is considered as constant because Caco-2 cells are quiescent.
Therefore the amount of available binding sites can be expressed as:
DNAfree~DNAtot{½DNATOP1 {½Compl {½Icompl .
d½TOP1 
dt
~kftop{kdtop½TOP1 {kf1½TOP1 ½DNAfree 
zkr1½DNATOP1 zkr2½Compl 
ð8Þ
d½DNATOP1 
dt
~kf1½TOP1 ½DNAfree 
{kf2½DNATOP1 ½SNin {kr1½DNATOP1 
ð9Þ
d½Compl 
dt
~kf2½DNATOP1 ½SN38in 
{kr2½Compl {kIrr½Compl 
ð10Þ
d½Icompl 
dt
~kIrr½Compl ð 11Þ
We consider that the first period of oscillations was artificially
perturbed by the serum shock and start the simulation at the
second one from which steady oscillations are expected in mRNA
and protein amounts. Protein intracellular concentrations are
modeled as the result of a constant degradation (kd) and a
circadian translation of period T, the intrinsic one, mean value M,
amplitude A and phase w. T is set to the period determined using
the mRNA quantifications shown in Figure 3. M and kd are set to
1 such that the mean value of the protein concentration is equal to
1. Those parameter values result in a delay between mRNA and
protein amounts approximately equal to 1h30, a duration
accounting for protein synthesis in cultured cells. For each gene,
w is set to the phase estimated from the corresponding mRNA
measurement (Table 1). Thus A is the only parameter to be
estimated for each protein. It is searched in the interval [0, 1]. This
range does not imply any assumption about the protein circadian
variation as the amplitude A can be equal to zero which
corresponds to an absence of rhythm. Of note, the modeled
protein concentrations only account for functional proteins and
can thus be interpreted as protein activities.
d½Protein 
dt
~MzAcos(
2p
T
(t{w)){kd½Protein ð 12Þ
Although TOP1 mRNA expression displayed robust circadian
variations, its nucleic protein level was constant in Caco-2 cells.
Therefore no circadian control is assumed on TOP1 protein
amount (see equation 7). As experimental transcriptional results
showed circadian rhythms for UGT1A1, CES2 and four ABC
transporters and as no information is available on corresponding
activities, we assume possible circadian variations for glucuronida-
tion (UGT), bioactivation (CES) and efflux of CPT11 (ABC_CPT)
and SN38 (ABC_SN). Equation 11 is used to model them.
Parameter estimation was performed by a bootstrap approach
using experimental results in Caco-2 cells and information from
the literature. The first step of the estimation consisted in
determining correct search intervals for each parameter, which
we did by using unpublished data on Caco-2 cells together with
existing information from literature (Text S1). For some
parameters (e.g. kupCPT), the search interval was very narrow
and this first step constituted the essential effort of estimation. The
second step consisted in fitting the model to the biological results
on CPT11 and SN38 pharmacokinetics (Figure 2) and CPT11
chrono-pharmacodynamics (Figure 4). This was performed by a
bootstrap approach in which 50 datasets were generated from the
original data. Then the model was fitted to each of these 50
datasets by a least-square approach in which the minimization task
was performed by the CMAES algorithm [38]. We thus got 50
parameter sets from which we computed the mean and standard
deviation of each parameter (Text S1).
When fitting the model to the experimental results of Figure 2,
verapamil exposure was assumed to exert an influence only on the
parameter VeffCPT which stands for the activity of CPT11 efflux
transporters. Therefore all the parameters were assumed to be the
same in presence or absence of verapamil except VeffCPT which
becomes VeffCPTvera (Table 2).
The parameter estimation provided a value for CES circadian
amplitude which was by far larger than that of all other proteins.
The amplitude of CES was actually greater than that of UGT,
ABC CPT,a n dABC SN in all the 50 parameter sets computed
by the bootstrap approach (Table 2). The standard deviations of
AUGT, AABC CPT and AABC SN were in the same range as the
parameter values which suggested that experimental data could still
be fitted by the model even if those circadian amplitudes were close
to zero (Table 2). This prefigured a weak influence of those protein
circadian rhythms on CPT11 chronotoxicity in Caco-2 cells.
Theoretical optimization of CPT11 exposure
For therapeutics optimization, well-synchronized Caco-2 cells
were considered as healthy cells whereas non-synchronized cells
represented cancer cells since circadian organization is often
Optimization of Irinotecan Circadian Delivery
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cancer cells were simulated using the same mathematical model of
CPT11 PK-PD. Parameter values were the same except for
circadian amplitudes A which were set to zero for tumor cells.
The considered exposure schemes consisted in an administra-
tion of CPT11 at a particular initial concentration, starting at a
particular CT, over a duration ranging from 1 to 27 h. The
cumulative dose is here defined as the initial concentration of
CPT11 multiplied by the exposure duration. We chose such
schemes because they are easily reproducible in cell culture.
CPT11 remained in the blood of cancer patients over approxi-
mately 24 h at a concentration ranging from 0 to 20 mM [8].
Therefore, we investigated cumulative doses ranging from 0 to
1440mM:h which corresponded to an exposure to 0 to 60mM of
CPT11 over 24 h. The optimization procedures which follow
consisted in determining the optimal values of the cumulative
dose, the CT at which the exposure started and its duration.
Maximizing efficacy without toxicity constraint. We
firstly only considered cancer cells and aimed at maximizing
efficacy without taking into account CPT11 toxicity on the healthy
cell population. As tumor cells are not synchronized, the CT of
exposure has no influence. We therefore looked for optimal values
of the cumulative dose and the exposure duration which induced
the largest DNA damage. Mathematically, this damage was
assessed by the value of the variable Icompl at the end of the
exposure. It was computed for a cumulative dose ranging from 0
to 1440mM:h and an exposure duration between 1 and 27 h
(Figure 5). For all the considered cumulative doses, optimal
durations ranged from 1h50 to 7h40 and increased with the dose.
As expected, the maximum efficacy for a given cumulative dose
increased with the cumulative dose.
Minimizing toxicity without efficacy constraint. We then
only considered healthy cells and aimed at minimizing toxicity
without any constraint of minimum efficacy. Toxicity was here
assessed by the value of DNA damage Icompl in the normal cell
population, at the end of the exposure. The cumulative dose of
CPT11, the CT at which the exposure started and its duration
were the three parameters considered here. To study the influence
of the CT and the exposure duration, we set the cumulative dose
to 500mM:h as an example, the following features remaining true
for all cumulative doses ranging from 0 to 1440mM:h. Toxicity
was computed for an exposure duration between 1 and 27 h, and
a CT of exposure ranging from CT0 to CT54, which
corresponded to two periods (Figure 6).
For any exposure duration, the best tolerated scheme was
obtained by starting CPT11 administration between CT2 and
CT3. This time interval corresponded to 1 to 2 h before the nadir
of CES protein amount (Figure 6, 7 A). The most toxic scheme
was achieved when CPT11 was administered at CT21 over the
exposure duration which also induced the largest DNA damage in
cancer cells (4 h for the dose of 500mM:h). This most toxic
duration displayed the largest circadian amplitude in terms of
DNA damage induced in healthy cells. CT21 did not correspond
exactly to the peak of CES protein amount but was rather the
optimal balance between high CES protein amount and low
UGT, ABC CPT and ABC SN ones.
Maximizing efficacy under a constraint of minimal
toxicity. Finally, in the perspective of control theory [40], we
adopted the therapeutics strategy of maximizing DNA damage on
cancer cells under the constraint of DNA damage on healthy cells
not exceeding a tolerability threshold. In a clinical point of view,
this threshold represents the maximum toxicity that the patient
can handle and may vary according to gender, genetic background
or previous treatments. Healthy and cancer cells were numerically
exposed to the same drug schedule mimicking the in vivo situation
in which healthy and tumor tissues are exposed to the same blood
concentrations.
The optimization procedures consisted in determining the
optimal values of the cumulative dose, the CT at which the
exposure started and its duration. Concerning the numerical
algorithm, a cost function was minimized to determine optimal
schemes for each value of the tolerability threshold. This function
was the sum of two terms: the first one was the opposite of DNA
damage Icompl in cancer cells, the second one was the toxicity
constraint which took the form of an If statement equal to 0 if
Icompl in healthy cells was below the toxicity threshold and 103
otherwise. The weight on the constraint was intentionally very
high in order to unconditionally maintain the toxicity under the
threshold. The algorithm CMAES was used to minimized the cost
function. It was preferred to Matlab function fmincon as it was able
to handle the large discontinuities of the cost function due to the
constraint. We investigated tolerability thresholds ranging from
0.01 to 0.04 nM of SN38 bound to DNA which corresponded to
the studied range of cumulative doses.
Table 2. Parameter values of the CPT11 molecular PK-PD
model.
Reaction Symbol Value
CPT11 uptake speed kupCPT 3:64+0:53h
{1
CPT11 efflux VeffCPT 594:35+116:64h
{1
KeffCPT 57:72+17:85mM
CPT11 efflux in presence of
verapamil
VeffCPTvera 409:3+66:09h
{1
CPT11 activation Vces 1:9+0:51h
{1
Kces 147:34+34:98mM
SN38 uptake kupSN 27:01+4:73h
{1
SN38 efflux VeffSN 161:18+46:24h
{1
KeffSN 1:28+0:57mM
SN38 glucuronidation Vugt 65:59+23:25h
{1
Kugt 2:69+0:9mM
DNATOP1 complex formation kf1 0:75+0:21 mM{1h
{1
DNATOP1 complex dissociation kr1 118:33+35:12h
{1
DNA/TOP1/SN38 complex
formation
kf2 2432:42+967:28mM
{1h
{1
DNA/TOP1/SN38 complex
dissociation
kr2 2:56+0:77h
{1
Irreversible complex formation kIrr 0:0035+0:0025h
{1
Entry sites on DNA for TOP1
binding
kentry 10:42+3:1pairsofbases
TOP1 protein formation kftop 0:018+0:009mM:h
{1
Amplitude of CPT11 bioactivation
circadian rhythm
ACES 0:9+0:09mM:h
{1
Amplitude of CPT11 efflux
circadian rhythm
AABC CPT 0:37+0:32mM:h
{1
Amplitude of SN38 efflux
circadian rhythm
AABC SN 0:22+0:18mM:h
{1
Amplitude of SN38
glucuronidation circadian rhythm
AUGT 0:45+0:31mM:h
{1
Values correspond to means+SD. They were estimated by fitting experimental
data on Caco-2 cells by a bootstrap approach (Results and Text S1).
doi:10.1371/journal.pcbi.1002143.t002
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PLoS Computational Biology | www.ploscompbiol.org 7 September 2011 | Volume 7 | Issue 9 | e1002143Figure 5. Mathematical optimization of CPT11 exposure in non-synchronized Caco-2 cells. Efficacy in non-synchronized cells with respect
to the cumulative dose and the exposure duration. White dots are the most efficient duration for each cumulative dose.
doi:10.1371/journal.pcbi.1002143.g005
Figure 6. Mathematical optimization of CPT11 exposure in synchronized Caco-2 cells. Toxicity in synchronized cells with respect to
exposure duration and CT of beginning of exposure. The cumulative dose was set to 500mM:h.
doi:10.1371/journal.pcbi.1002143.g006
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241 to 1321mM:h and increased with the tolerability threshold.
For any dose, the optimal scheme consisted in administering
CPT11 over 3h40 to 7h10 starting between CT2h10 and CT2h30
which corresponded to 1h30 to 1h50 before the nadir of CES
protein amount (Figure 7). The optimal schemes were not centered
on the nadir of CES rhythm but rather extended after it, when
UGT, ABC CPT and ABC SN amounts were higher and
therefore protected more efficiently healthy cells. For any
maximum allowed toxicity, the optimal duration did not exceed
7h10 highlighting the need of short exposure durations to
optimally exploit the temporal difference between healthy and
cancer cells. Regarding efficacy, those optimal schemes induced
twice more DNA damage in cancer cells than in healthy ones.
Discussion
We gave evidence for a circadian organization in Caco-2 cells
resulting in rhythms in CPT11 PD. A mathematical model of
CPT11 molecular PK-PD was designed, fitted to experimental
results and used for therapeutics optimization. It concluded that
any dose of CPT11 should be optimally administered over a
duration of 3h15 to 7h10, starting between 1h30 and 1h50 before
the nadir of CPT11 bioactivation rhythm.
A clinical interpretation of the optimal therapeutics strategies
presented in this in vitro study can be obtained by rescaling the
period from 27 h, that of Caco-2 cells, to 24 h. It thus suggests to
administer CPT11 such that it remains over an active concentra-
tion in the patient blood during 3h30 to 6h30, starting between
1h20 and 1h40 before the nadir of the patient’s circadian rhythm
of CESs. In cancer patients, a dumbbell delivery scheme over 6h
resulted in CPT11 circulating during approximately 12 h [8]. The
present study thus suggests to reduce the duration of CPT11
infusion which may enhance efficacy. This might also lead to a
decrease in the total administered dose in order to achieve
acceptable tolerability.
SN38 was detected in Caco-2 cells which is in agreement with
the fact that CES2 was expressed. Its efflux was not influenced by
verapamil suggesting a weak activity of the inhibitor on
transporters responsible for SN38 efflux. Indeed, ABCG2 for
which SN38 is a good substrate, is poorly inhibited by verapamil
[41]. Another possibility is that SN38 efflux was not mediated by
active transporters, the highly lipophilic molecules of SN38
diffusing passively across the cell membrane.
Figure 7. Maximizing CPT11 efficacy under a constrainst of tolerability. A: Simulated circadian rhythm of CES (green), UGT (blue),
ABC CPT (red) and ABC SN (orange) protein amounts in healthy cells. B: Optimal exposure schemes following the strategy of maximizing efficacy
under a constraint of maximal allowed toxicity. Optimal schemes consisted in administering the optimal cumulative dose (written in green) over 3h40
to 7h10, starting between 1h30 and 1h50 before the nadir of CES protein amount. Schemes were not centered on the nadir but rather extended after
it when UGT, ABC CPT and ABC SN amounts were higher and protected more efficiently healthy cells.
doi:10.1371/journal.pcbi.1002143.g007
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metabolites: APC and NPC [16]. Those pathways were not taken
into account as they are reported to be inactive in most Caco-2 cell
lines [42]. Nevertheless verapamil inhibits cytochrome P450 3A
[43] and the drastic increase of CPT11 intracellular concentration
in the presence of verapamil could be explained by the decrease in
CPT11 conversion into APC and NPC.
Only 0.1% of CPT11 dose was bioactivated into SN38 in Caco-
2 cells (Figure 2). Our data suggest that the remaining 99.9%
exerted weak cytotoxicity as described in the literature [17].
Indeed verapamil exposure of Caco-2 cells resulted in a 10-fold
increase in the intracellular concentration of CPT11 without any
change in that of SN38. In contrast with those large pharmaco-
kinetics differences, the average percentage of surviving cells after
exposure to verapamil and CPT11 was only reduced by 11.6%
relative to that measured when cells were exposed to CPT11
alone. In the light of those experimental results, it seemed justified
to neglect CPT11 activity in the current mathematical model.
The protein degradation (i.e. kd) was assumed to be constant as
no biological data were available regarding its circadian variations
for each considered enzyme. However, this assumption must be
tempered since circadian changes could modulate the phosphor-
ylation processes occurring upstream of protein degradation [44].
The mathematical model predicted that CPT11 bioactivation
through CES was the main determinant of CPT11 PD circadian
rhythm. Even though the circadian amplitude of CES2 mRNA
expression was the lowest among all measured genes, its protein
amount and activity could be highly rhythmic. Indeed CES1
protein level displayed robust circadian variations in the colon
mucosa of two mouse strains despite low amplitude of the
circadian variations of its mRNA level [2]. Nevertheless, the 1h30-
delay between mRNA and protein expression assumed in the
mathematical model might be underestimated [45] and UGT1A1
or ABC transporters may have been determinant for CPT11 PD
rhythm. However this hypothesis was not favored as the shifts
between their mRNA and protein expressions must have exceeded
ten hours to be relevant.
Here, a realistic interval of values was determined for each
parameter. Thus our mathematical model constitutes a reasonable
tool to explore therapeutics optimization in the perspective of
clinical applications. However, more biological information is
needed to determine precise values of all parameters in the Caco-2
cell line and therefore be able to predict its quantitative response to
CPT11.
CPT11 activity was assessed by the amount of irreversible
CPT11/TOP1/DNA complexes. Those complexes trigger DNA
repair and possibly lead to apoptosis [46]. Many repair enzymes as
well as proteins involved in the apoptotic machinery such as p53,
the pro-apoptotic BAX or the anti-apoptotic BCL-2 display
circadian rhythms which may influence CPT11 chronotoxicity
[2,47–49]. Therefore DNA repair and apoptosis enzymes should
both be studied in Caco-2 cells and included in an extended
version of the mathematical model.
In the current model we differentiated cancer cells from healthy
ones by their lack of circadian entrainment. The proliferation rate
constitutes another important difference which was not considered
here as we studied quiescent cells. Our mathematical model has
been supplemented with a circadian entrained cell cycle model in
order to optimize CPT11 exposure in proliferating cells [50].
This study on cell populations is being further integrated into a
whole-body physiologically-based PK-PD model which aims at
investigating molecular differences between experimentally-deter-
mined chronotoxicity mouse classes and designing optimal
administration schemes for each of them [2]. This prefigures the
part of mathematical modeling in the determination of patient
classes characterized by molecular biomarkers according to which
the circadian delivery would be tailored. In the case of colorectal
cancer, patients often undergo surgery after which tumor and
healthy cells can be collected and analyzed at the molecular level
[36,51]. The whole body mathematical model could then be fitted
to the patient molecular profile and provide a tailored chron-
omodulated administration scheme.
Materials and Methods
Cell culture
The Caco-2 cell line was obtained from the American Type
Culture Collection (Rockville, MD). Cells were grown in
Dulbecco’s modified Eagle’s: Ham F12 medium (1:1) supplement-
ed with penicillin (100 U/L), streptomycin (100mg:mL{1),
glutamine (2 mM) (Fischer Scientific, Paris, France) and 10% of
Fetal Bovine Serum (FBS) (Dutscher, Paris, France). They were
maintained in a humidified atmosphere containing 5% CO2 at
37oC. Experiments were performed four days after confluence.
CPT11 was purchased from Pfizer (Paris, France). For transport
inhibition studies, non-synchronized cells were pre-incubated with
verapamil, a non specific inhibitor of ABC transporters (100mM
for 24 h; Sigma Aldrich, Paris, France) [52]. Cells were then
exposed to CPT11 (115mM) during 48 h. Cell synchronization was
performed by a serum shock which consisted in a 2-hour exposure
to serum rich medium (DMEM:F12 containing 50% FBS). The
beginning of the serum shock defined Circadian Time 0 (CT 0).
RNA quantification
Circadian gene expressions were estimated using quantitative
Real-Time Polymerase Chain Reaction (qRT-PCR). Cells were
scraped at different CTs in guanosine isothiocyanate and frozen at
{80oC until RNA extraction performed as described in [53].
Reverse transcription was achieved with Superscript II RT
(Invitrogen, Paris, France). Quantitative PCRs were performed
with LightCycler 480 using LightCycler 480 SYBR Green I
master kit (Roche, Meylan, France). Relative quantification of
target RNA using 36B4 as reference was performed with Relquant
software (Roche, Meylan, France).
CPT11 lactone-carboxylate equilibrium
CPT11 mother solution being at pH 4.4, CPT11 underwent a
transformation from its lactone to carboxylate form when it was
added to the culture medium at pH 7.8. In order to assess the
duration of this reaction, we built a mathematical model and fitted
it to data from [54] (Text S1). In our experimental conditions the
model predicted that the lactone/carboxylate equilibrium was
reached within 3 h. The culture medium containing CPT11 was
therefore prepared more than 3 h before incubation with cells.
Drug concentration measurement
CPT11 and SN38 extra- and intracellular concentrations were
measured by a method of High Performance Liquid Chromatog-
raphy (HPLC) adapted from [55]. After cell exposure, extracel-
lular medium was sampled. The cell layers were rinsed with
Phosphate Buffer Saline (PBS), recovered by scraping and pelleted
in 1 mL of PBS. Cells were then centrifuged. Cell pellets were
resuspended in 100 mL of water supplemented with 200mL of
methanol/acetonitrile (50/50 v/v) containing 1% HCl. Cells were
centrifuged again and the supernatant containing drugs was
sampled. 70 mL was diluted by adding 30mL of water and spiked
onto the column. Extracellular samples were diluted ten times,
pretreated with acetonitrile 1% trifluoroacetic acid and centri-
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reversed-phase column (Interchim, Montlucon, France) with a
mobile phase consisting of a mixture of water, acidified acetonitrile
(0.005% of trifluoroacetic acid) and methanol (50:38:12, v/v/v).
This mobile phase was delivered isocratically at a flow rate of
0.6 mL/min with a P680 pump (Dionex Corporation, Sunnyvale,
CA). Fluorometric detection was carried out with excitation and
emission wavelengths set at 380 and 532 nm respectively, using
the RF-2000 detector (Dionex Corporation). Peaks were quanti-
fied by reference to a standard calibration curve obtained by
spiking known amounts of drugs (CPT11 (0:001{0:1mg:mL{1)
and SN38 (5:10{5{5:10{2mg:mL{1)), using WinNonLin Pro
software (Pharsight Corporation, Mountain View, CA). The values
obtained from HPLC measurement were normalized to one
million cells (Text S1).
TOP1 activity
The Topo I Link Kit (TopoGen, Port Orange, FL) was used to
quantify the amount of TOP1 linked on DNA [56]. The cells were
lysed with 3 mL lysis buffer. Cell lysates were loaded at the top of a
cesium chloride gradient and centrifuged at 100,000 g for 16 h at
20oC. Fractions of 400mL were removed from the top of the
gradient, and an aliquot of each fraction (10mL) was diluted (1/5)
and quantified at 260 nm with spectrophotometer (Eppendorf,
Paris, France). In parallel, another aliquot of each fraction (50mL)
was diluted with an equal volume of 25 mM sodium phosphate
buffer and loaded onto a nitrocellulose membrane (Perbio, Paris,
France) using a slot-blot device. TOP1 was revealed in the slots
with the immunoblotting technique described in the TopoGen kit
using ProteinA-peroxidase (1/5000, Sigma Aldrich, Paris, France)
to replace secondary antibody. A signal was seen in two different
groups of slots: those not containing DNA (free TOP1, top of the
gradient) and those containing DNA (DNA/TOP1 complexes,
bottom of the gradient). Chemoluminescence signals were detected
with Las4000 camera and quantified with ImageJ software. For
circadian assessment of TOP1 complexes after CPT11 exposure
cells were exposed during 30 min at 50mM at indicated CT. The
software SPSS (IBM, Somers, NY) was used for the Anova test
(univariate general linear model).
Gene expression mathematical model
Circadian gene expressions in synchronized Caco-2 cells were
modeled as a damped cosine:
RNA(t)~Rze{lt(PzScos(
2p
T
(t{w))) ð13Þ
The damping factor e{lt was both applied to the cosine to
represent cell desynchronization over time and to P to model the
initial overexpression of genes due to the serum shock. Both
dampening exponents were assumed to be equal for the sake of
simplicity. R represented the mRNA value before the serum shock
towards which the model converges in long time. All genes were
assumed to oscillate with the same period which was the cell
population intrinsic one. This common period T and gene
parameters R, l, P, S, and w were estimated simultaneously for all
genes using a bootstrap approach to fit experimental results of
Figure 3 (Text S1).
Minimization algorithms
Matlab function fmincon and the CMAES algorithm [38] were
used for minimization tasks in parameter estimations and
optimization procedures.
Supporting Information
Text S1 Supporting Information concerning Materials and
Methods and parameter estimation.
(PDF)
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